Visiopharm AI-driven Precision Pathology
by Visiopharm
· Based in Denmark →
— AI-driven precision pathology software for research and diagnostics.
Overview
Visiopharm AI-driven Precision Pathology is an image analysis software platform that utilizes artificial intelligence and deep learning for quantitative tissue analysis in both research and diagnostics. It is designed for pathologists, researchers, and image analysis experts.
- What it does: The platform provides tools for analyzing digital pathology images, enabling quantification of biomarkers, cell phenotypes, and spatial relationships within tissue. It includes modules for spatial biology analysis (Phenoplex™), general tissue image analysis (Discovery), and assessment of IHC staining consistency (Qualitopix).
- Who it is for: This tool is intended for pathologists in diagnostic settings, as well as scientists and researchers in academic institutions and the biopharmaceutical industry.
- How it fits a clinical or practice workflow: Visiopharm offers IVDR-certified CE-IVD APPs for diagnostic decision support, particularly for biomarker assessment in breast, lung, and prostate cancer. These applications are designed for integration into existing laboratory workflows, including PACS, IMS, and LIS systems, to facilitate automated analysis and provide results for pathologist review.
- Notable capabilities: The platform features an APP Center with over 130 modular image analysis units, including pretrained “Quickstart APPs” that can be customized. It supports deep learning-based classification and offers tools for tissue detection, regional segmentation, and cellular compartment definition. Visiopharm’s solutions have been featured in over 3,500 scientific publications.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-Powered Image Analysis
- Automated Tissue Detection
- Quantitative Analysis
- Continuous Learning
- Comprehensive Data Management
- Seamless System Integration
- Pretrained Quickstart APPs
- Deep Learning for custom APP training
- Spatial Biology Analysis (Phenoplexu2122)
- IHC Staining Consistency Measurement (Qualitopix)
Use Cases
- Biomarker assessment in breast cancer, lung cancer, and prostate cancer
- Metastasis detection in H&E stained lymph nodes for breast and colorectal adenocarcinoma
- Spatial biology research and analysis
- Drug discovery and development
- Clinical research and diagnostics
- IHC staining consistency measurement and documentation
What Physicians Need to Know
Key Capabilities
Visiopharm provides AI-driven precision pathology software for both research and diagnostics. It offers image analysis software that combines deep learning AI with extensive knowledge from pathologists and research scientists. Key capabilities include automated tumor detection, cell segmentation, multiplex phenotyping, and quantitative biomarker analysis. The platform also features pretrained 'Quickstart APPs' that can be fine-tuned for specific study needs, and an 'Author' module for developing customized, high-performance algorithms.
Clinical Utility
The software offers diagnostic decision support through IVDR certified CE-IVD APPs for biomarker assessment in breast cancer (HER2, ER, PR, Ki-67, metastasis detection), lung cancer (PD-L1), and prostate cancer (Gleason scoring). It aims to improve diagnostic accuracy, consistency, and efficiency in pathology labs by providing objective and reproducible results, minimizing false negatives, and enhancing sensitivity on prognostic and predictive biomarkers. Visiopharm also offers Qualitopix, an AI-based platform for IHC staining quality assurance, which uses quantitative analysis to monitor and document staining consistency.
Integration Options
Visiopharm's solutions are designed for seamless integration into existing lab workflows, including various Image Management Systems (IMS), Laboratory Information Systems (LIS), and Picture Archiving and Communication Systems (PACS). They are compatible with leading digital pathology platforms and scanners, including partnerships with Agilent, PathAI (AISight IMS), Proscia, Philips, Smart in Media, Fujifilm, Corista, Paige, Indica Labs (HALO Link), and Grundium Ocus scanners.
Compliance Status
Visiopharm is a leader in clinical applications with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. Their diagnostic APPs are validated and certified under IVDR, ensuring robust and integrated workflows for clinical biomarker scoring.
User Experience
The software is designed with an intuitive user interface, allowing users with an understanding of tissue morphology to train AI deep learning APPs. It prioritizes a 'zero-click workflow' to minimize manual interactions and integrate smoothly into existing systems, making results ready for review without extensive manual input. The platform also provides rich visual support, including AI-generated overlays and embedded quantitative results, to aid pathologists in decision-making.
Support Quality
Visiopharm has an experienced support team that assists customers with implementation and ongoing use, with a track record of successfully integrating their solutions into hospital and lab workflows across Europe since 2014.
Implementation Complexity
While implementing AI into digital pathology can seem challenging, Visiopharm aims to minimize disruption by prioritizing integrations and offering web-based, on-premise, or hybrid deployment options. The Qualitopix solution, for instance, is a web-based solution designed for seamless incorporation into existing workflows without significant implementation efforts.
Evidence Base
Visiopharm's diagnostic APPs are developed in close collaboration with pathologists and are validated and certified under IVDR. The company has been a leader in IVD certified APPs since 2014 and is the only company with a full portfolio of clinical APPs certified under IVDR since 2022. Studies have been conducted to validate the precision of their digital pathology pipeline, including scanners and image analysis algorithms, for IHC staining quality assurance. Validation of specific APPs, such as an eosinophil counting APP, has shown strong correlation with pathologist manual counts (Spearman r = 0.9895).
Physician Tip
Visiopharm's AI-driven precision pathology tools offer objective and consistent biomarker scoring, which can significantly enhance diagnostic accuracy and efficiency, especially for complex cases. Leverage the IVDR-certified APPs for breast, lung, and prostate cancer to standardize your diagnostic workflows. The ability to customize algorithms with the 'Author' module can be particularly useful for specific research needs or unique tissue characteristics. Utilize the staining quality assurance tools like Qualitopix to ensure consistency and reliability of IHC results, which is crucial for both clinical trials and routine diagnostics. The seamless integration with various IMS/LIS/PACS systems and scanners aims to minimize workflow disruption, allowing for a smoother transition to AI-augmented pathology. Always review the AI-generated overlays and quantitative results to make informed decisions, as the AI provides decision support rather than replacing the pathologist's expertise.
Visiopharm is committed to being platform-agnostic, ensuring broad compatibility with various digital pathology ecosystem components. The software integrates with major IMS/PACS systems such as Proscia, Sectra, PathAI (AISight IMS), Philips, Smart in Media, Fujifilm, Corista, Paige, and Indica Labs (HALO Link). It also supports integration with various slide scanners, including those from Hamamatsu and Grundium Ocus. This extensive interoperability allows laboratories to build a customized digital pathology ecosystem tailored to their specific needs and existing infrastructure, facilitating a 'zero-click workflow' and automated image processing.
Details
| Category | Oncology AI, Pathology AI |
| Pricing | Unknown — unknown |
| Deployment | On-premise, Cloud-based (via partners) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Unknown AI-estimated Visiopharm offers several diagnostic algorithms cleared under IVDR for EU and UK customers, providing diagnostic decision support. These CE-IVD APPs are for in vitro diagnostic use in the EU/UK and are not for sale in the USA, where translational APPs are available. |
| Integrations | |
| EHR | Not specified |
| Specialties | Laboratory Medicine, Oncology, Pathology |
What the Web Says
Visiopharm AI-driven Precision Pathology offers advanced image analysis solutions for pathology labs and research institutions, leveraging AI algorithms and deep learning techniques to enhance diagnostic accuracy and workflow efficiency. The platform aims to revolutionize digital pathology by providing unparalleled precision in image interpretation, automated tissue detection, and quantitative analysis for multiple tissue markers. Recent updates have focused on improving user experience with tools like the Phenoplex Guided Workflow for cell phenotyping and an advanced color adjustment menu for complex images.
Overall: PositiveStrengths
- AI-powered image analysis for unparalleled precision and automated tissue detection.
- Enhanced diagnostic accuracy and workflow efficiency.
- Seamless integration with existing lab infrastructure and compatibility with major platforms.
- Comprehensive data management with scalable storage and advanced search capabilities.
- User-friendly interface and intuitive setup process.
- Reduced slide review time and potential for cost savings on unnecessary IHC use.
Limitations
- No user reviews found on Appvizer, G2, or Capterra.
- Limited information available regarding specific pricing on publicly accessible review sites.
- No integrations listed on SourceForge.
- Implementing AI into existing workflows can seem like an uphill task, though Visiopharm prioritizes minimizing disruption.
Based on reviews from: Appvizer, OracleBio, SourceForge, Visiopharm (official website), Pulse 2.0, Tissuepathology.com, Bruker Spatial Biology, Massachusetts General Hospital, Glint Lab, CIO Applications, Azorg, Lab Manager, Alimentiv, Digital Pathology Place
Last updated: 2026-08-08
Ratings & Reviews
Rate Visiopharm AI-driven Precision Pathology
Press & Coverage
Visiopharm / Grundium / Pulse 2.0 / EU-Startups / AIPressRoom
Grundium acquires Visiopharm to create integrated precision pathology platform
Grundium has acquired Visiopharm, combining digital slide scanning with AI-driven precision pathology software to create an integrated end-to-end solution for diagnostic laboratories, biopharmaceutical development, and research. This acquisition aims to accelerate the adoption of precision diagnostics by offering more accessible and scalable digital pathology.
2026-05
Visiopharm
Advancing Preclinical Lung Research with Automated Image Analysis: Interview with Simone de Meo, from Chiesi Farmaceutici
This article features an interview discussing the advancement of preclinical lung research through automated image analysis, highlighting Visiopharm's role in providing tools for accurate data production in tissue-based research.
2026-07
Visiopharm
Flexible analysis for veterinary pathology: Interview with Simone de Brot
An interview with Simone de Brot discusses the application of flexible analysis methods in veterinary pathology, likely leveraging Visiopharm's AI-driven software for diverse tissue-based research.
2026-06
Visiopharm
Tech Talk #1: Faster AI Training, Tissue Alignment, and more in Visiopharm platform
Visiopharm released a 'Tech Talk' detailing new features in its platform, including faster AI training and improved tissue alignment, aimed at enhancing the efficiency and accuracy of AI-driven pathology analysis.
2026-06
Visiopharm
Cell Signaling Technology and Visiopharm Announce Partnership to Advance Spatial Biology Research
Cell Signaling Technology (CST) and Visiopharm have partnered to advance spatial biology research by combining CST's multiplex IHC technology with Visiopharm's Phenoplex software for streamlined image analysis. This collaboration aims to enable more efficient interrogation of cellular interactions in the tumor microenvironment and accelerate biomarker discovery.
2025-04
Visiopharm
Visiopharm's Precision Pathology APPs to be Integrated with PathAI's AISight Image Management System
Visiopharm is partnering with PathAI to integrate its precision pathology APPs, including breast and lung cancer panels, into PathAI's AISight Image Management System. This integration aims to transform diagnostic and translational pathology workflows by providing users with enhanced accuracy and speed in image analysis.
2024-11
Visiopharm
Visiopharm and UMC Utrecht achieve breakthrough in AI-powered detection of breast cancer lymph node metastases
Visiopharm's AI application for detecting metastatic breast cancer in lymph nodes has been validated by UMC Utrecht, achieving 100% sensitivity for clinically relevant metastases and reducing pathologist assessment time by 39%. The study was published in Nature Cancer, highlighting the potential of AI in transforming cancer diagnostics.
2024-06
Visiopharm
Visiopharm and Agilent partner to accelerate precision medicine with AI-driven precision pathology solutions for pharma
Visiopharm and Agilent Technologies have formed a strategic partnership to provide advanced AI-driven precision pathology solutions for pharmaceutical companies. This collaboration aims to accelerate precision medicine by improving patient selection in clinical trials and supporting diagnostic applications through standardized biomarker expression.
2023-04
Videos
Product demos, reviews, and walkthroughs for Visiopharm AI-driven Precision Pathology.
Loading videos...
Frequently Asked Questions
Visiopharm's AI algorithms are designed to seamlessly integrate with standard digital pathology workflows, allowing for analysis of whole slide images from various scanners. The platform provides quantitative data and insights that can be incorporated into your diagnostic reports and treatment planning, augmenting your current practices rather than replacing them.
Visiopharm's AI algorithms for precision pathology are developed and validated according to rigorous regulatory standards. Specific regulatory clearances (e.g., CE-IVD, FDA) vary by algorithm and region, and detailed documentation is available to demonstrate their analytical and clinical validity for oncology applications.
Current limitations of AI in pathology can include the need for high-quality, well-annotated training data, generalizability across diverse patient populations, and the 'black box' nature of some algorithms. Visiopharm addresses these by employing extensive, diverse datasets for training, focusing on explainable AI models, and providing transparent validation data to build physician confidence.
Visiopharm's AI solutions are rigorously benchmarked against both traditional manual methods and other AI platforms, demonstrating superior accuracy and efficiency in specific oncology diagnostic tasks. Our algorithms are designed to reduce inter-observer variability and provide quantitative metrics that are difficult or impossible to obtain manually, leading to more consistent and precise diagnoses.
Visiopharm offers flexible pricing models, which can include per-slide fees, subscription-based access, or perpetual licenses, depending on the specific modules and scale of use. The aim is to provide a cost-effective solution that enhances diagnostic throughput, improves accuracy, and ultimately contributes to better patient outcomes, potentially reducing overall healthcare costs by optimizing treatment pathways.
Yes, Visiopharm's AI is being developed and validated for its ability to identify subtle morphological patterns indicative of rare cancer subtypes that may be challenging for the human eye to detect consistently. Furthermore, certain algorithms are designed to extract prognostic and predictive biomarkers from tissue, aiding in the prediction of treatment response and patient stratification in oncology.
Visiopharm provides comprehensive training programs tailored to pathologists and their laboratory teams, covering everything from basic software navigation to advanced interpretation of AI-generated results. Ongoing technical support, clinical application specialists, and educational resources are also available to ensure a smooth integration and optimal utilization of the platform within your oncology practice.
Suggest an Edit →
| Last Verified: 2026-08-05 | First Added: 2026-08-05